{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:05:37Z","timestamp":1761523537596},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T00:00:00Z","timestamp":1123545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1038\/sj.bjc.6602733","type":"journal-article","created":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T17:07:46Z","timestamp":1123607266000},"page":"510-514","source":"Crossref","is-referenced-by-count":49,"title":["Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan"],"prefix":"10.1038","volume":"93","author":[{"given":"G","family":"Chong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L B","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T J","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Oates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Tebbutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,8,9]]},"reference":[{"key":"BF6602733_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/07357909909032844","volume":"17","author":"N Anderson","year":"1999","unstructured":"Anderson N, Lokich J, Moore C, Bern M, Coco F (1999) A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. Cancer Invest 17: 586\u2013593","journal-title":"Cancer Invest"},{"key":"BF6602733_CR2","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084\u20132091","journal-title":"J Clin Oncol"},{"key":"BF6602733_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1023\/A:1008356017611","volume":"11","author":"JD Chester","year":"2000","unstructured":"Chester JD, Dent JT, Wilson G, Ride E, Seymour MT (2000) Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 11: 235\u2013237","journal-title":"Ann Oncol"},{"key":"BF6602733_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337\u2013345","journal-title":"N Engl J Med"},{"key":"BF6602733_CR5","unstructured":"Harba A, Jordan K, Kegel T, Behrens R, Grothey A, Schmoll HJ (2003) Capecitabine\/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma. Proc Am Soc Clin Oncol 22: (abstr. 1335) p332"},{"key":"BF6602733_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00001813-199806000-00009","volume":"9","author":"JT Hartmann","year":"1998","unstructured":"Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L, Bokemeyer C (1998) Phase II study of continuous 120\u2009h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 9: 427\u2013431","journal-title":"Anticancer Drugs"},{"key":"BF6602733_CR7","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282\u20132292","journal-title":"J Clin Oncol"},{"key":"BF6602733_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2004.05.072","volume":"22","author":"PM Hoff","year":"2004","unstructured":"Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL (2004) Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22: 2078\u20132083","journal-title":"J Clin Oncol"},{"key":"BF6602733_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/sj.bjc.6602025","volume":"91","author":"RD Hofheinz","year":"2004","unstructured":"Hofheinz RD, Hartmann JT, Willer A, Oechsle K, Hartung G, Gnad U, Saussele S, Kreil S, Bokemeyer C, Hehlmann R, Hochhaus A (2004) Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer 91: 834\u2013838","journal-title":"Br J Cancer"},{"key":"BF6602733_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","volume":"55","author":"T Ishikawa","year":"1998","unstructured":"Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091\u20131097","journal-title":"Biochem Pharmacol"},{"key":"BF6602733_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3816\/CCC.2004.n.009","volume":"4","author":"K Jordan","year":"2004","unstructured":"Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A (2004) Phase II trial of capecitabine\/irinotecan and capecitabine\/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 4: 46\u201350","journal-title":"Clin Colorectal Cancer"},{"key":"BF6602733_CR12","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1200\/JCO.2004.03.119","volume":"22","author":"N Kemeny","year":"2004","unstructured":"Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Schwab BD, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil\/leucovorin compared with fluorouracil\/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22: 4701\u20134709","journal-title":"J Clin Oncol"},{"key":"BF6602733_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00280-004-0963-2","volume":"56","author":"H Lim do","year":"2005","unstructured":"Lim do H, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K (2005) Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56: 10\u201314","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6602733_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3816\/CCC.2004.n.004","volume":"3","author":"TJ Price","year":"2004","unstructured":"Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D (2004) Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 3: 235\u2013242","journal-title":"Clin Colorectal Cancer"},{"key":"BF6602733_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/sj.bjc.6602039","volume":"91","author":"S Rao","year":"2004","unstructured":"Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P (2004) Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 91: 839\u2013843","journal-title":"Br J Cancer"},{"key":"BF6602733_CR16","first-page":"2981","volume":"23","author":"G Rosati","year":"2003","unstructured":"Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L (2003) Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23: 2981\u20132985","journal-title":"Anticancer Res"},{"key":"BF6602733_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008263516099","volume":"8","author":"P Ross","year":"1997","unstructured":"Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995\u20131001","journal-title":"Ann Oncol"},{"key":"BF6602733_CR18","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013\u20131019","journal-title":"Clin Cancer Res"},{"key":"BF6602733_CR19","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097\u20134106","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602733","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:17:39Z","timestamp":1684412259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF6602733"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602733","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,9]]}}}